Oxurion NV: Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Leuven, BELGIUM, Boston, MA, US - May 3, 2022 - 7:10 PM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies
Source: finanznachrichten.de